128 related articles for article (PubMed ID: 15056127)
1. The effect of valsartan on regression of left ventricular hypertrophy in type 2 diabetic patients.
Suzuki K; Kato K; Soda S; Kamimura T; Aizawa Y
Diabetes Obes Metab; 2004 May; 6(3):195-9. PubMed ID: 15056127
[TBL] [Abstract][Full Text] [Related]
2. Influence of the angiotensin II antagonist valsartan on left ventricular hypertrophy in patients with essential hypertension.
Thürmann PA; Kenedi P; Schmidt A; Harder S; Rietbrock N
Circulation; 1998 Nov; 98(19):2037-42. PubMed ID: 9808602
[TBL] [Abstract][Full Text] [Related]
3. Comparative effects of valsartan versus amlodipine on left ventricular mass and reactive oxygen species formation by monocytes in hypertensive patients with left ventricular hypertrophy.
Yasunari K; Maeda K; Watanabe T; Nakamura M; Yoshikawa J; Asada A
J Am Coll Cardiol; 2004 Jun; 43(11):2116-23. PubMed ID: 15172423
[TBL] [Abstract][Full Text] [Related]
4. The effect of valsartan on left ventricular myocardial functions in hypertensive patients with left ventricular hypertrophy.
Kucukler N; Kurt IH; Topaloglu C; Gurbuz S; Yalcin F
J Cardiovasc Med (Hagerstown); 2012 Mar; 13(3):181-6. PubMed ID: 22306782
[TBL] [Abstract][Full Text] [Related]
5. A selective angiotensin receptor antagonist, Valsartan, produced regression of left ventricular hypertrophy associated with a reduction of arterial stiffness.
Suzuki H; Nakamoto H; Okada H; Sugahara S; Kanno Y
Adv Perit Dial; 2003; 19():59-66. PubMed ID: 14763035
[TBL] [Abstract][Full Text] [Related]
6. Effects of valsartan or ramipril addition to amlodipine/hydrochlorothiazide combination on left ventricular mass in diabetic hypertensive patients with left ventricular hypertrophy.
Fogari R; Zoppi A; Mugellini A; Maffioli P; Preti P; Derosa G
Expert Opin Pharmacother; 2012 Jun; 13(8):1091-9. PubMed ID: 22515416
[TBL] [Abstract][Full Text] [Related]
7. Effects of combined therapy of Xuezhikang Capsule and Valsartan on hypertensive left ventricular hypertrophy and heart rate turbulence.
Gong C; Huang SL; Huang JF; Zhang ZF; Luo M; Zhao Y; Jiang XJ
Chin J Integr Med; 2010 Apr; 16(2):114-8. PubMed ID: 20473735
[TBL] [Abstract][Full Text] [Related]
8. Effects of valsartan and perindopril combination therapy on left ventricular hypertrophy and aortic arterial stiffness in patients with essential hypertension.
Anan F; Takahashi N; Ooie T; Yufu K; Hara M; Nakagawa M; Yonemochi H; Saikawa T; Yoshimatsu H
Eur J Clin Pharmacol; 2005 Jul; 61(5-6):353-9. PubMed ID: 15918057
[TBL] [Abstract][Full Text] [Related]
9. Comparison of the efficacy and safety profiles of two fixed-dose combinations of antihypertensive agents, amlodipine/benazepril versus valsartan/hydrochlorothiazide, in patients with type 2 diabetes mellitus and hypertension: a 16-week, multicenter, randomized, double-blind, noninferiority study.
Lee IT; Hung YJ; Chen JF; Wang CY; Lee WJ; Sheu WH
Clin Ther; 2012 Aug; 34(8):1735-50. PubMed ID: 22784975
[TBL] [Abstract][Full Text] [Related]
10. Angiotensin II receptor blocker, valsartan, increases myocardial blood volume and regresses hypertrophy in hypertensive patients.
Komatsu H; Yamada S; Iwano H; Okada M; Onozuka H; Mikami T; Yokoyama S; Inoue M; Kaga S; Nishida M; Shimizu C; Matsuno K; Tsutsui H
Circ J; 2009 Nov; 73(11):2098-103. PubMed ID: 19749478
[TBL] [Abstract][Full Text] [Related]
11. Enhanced cardiovascular protective effects of valsartan in high-risk hypertensive patients with left ventricular hypertrophy--sub-analysis of the KYOTO HEART study.
Shiraishi J; Sawada T; Kimura S; Yamada H; Matsubara H;
Circ J; 2011; 75(4):806-14. PubMed ID: 21436597
[TBL] [Abstract][Full Text] [Related]
12. Angiotensin II antagonism and the heart: valsartan in left ventricular hypertrophy.
Thürmann PA
J Cardiovasc Pharmacol; 1999; 33 Suppl 1():S33-6; discussion S41-3. PubMed ID: 10028952
[TBL] [Abstract][Full Text] [Related]
13. The efficacy of valsartan in essential hypertension and its effects on left ventricular hypertrophy.
Mutlu H; Ozhan H; Okçün B; Okuyan E; Yigit Z; Erbaş C; Küçükoglu MS; Gültekin N; Uner S; Erdine S; Güven O
Blood Press; 2002; 11(1):53-5. PubMed ID: 11926352
[TBL] [Abstract][Full Text] [Related]
14. Angiotensin II antagonism and the heart: valsartan in left ventricular hypertrophy.
Thürmann PA
Cardiology; 1999; 91 Suppl 1():3-7. PubMed ID: 10449888
[TBL] [Abstract][Full Text] [Related]
15. Renoprotective effects of low-dose valsartan in type 2 diabetic patients with diabetic nephropathy.
Suzuki K; Souda S; Ikarashi T; Kaneko S; Nakagawa O; Aizawa Y
Diabetes Res Clin Pract; 2002 Sep; 57(3):179-83. PubMed ID: 12126767
[TBL] [Abstract][Full Text] [Related]
16. Comparison of the effects of angiotensin receptor antagonist, angiotensin converting enzyme inhibitor, and their combination on regression of left ventricular hypertrophy of diabetes type 2 patients on recent onset hemodialysis therapy.
Suzuki H; Kanno Y; Kaneko K; Kaneko M; Kotaki S; Mimura T; Takane H
Ther Apher Dial; 2004 Aug; 8(4):320-7. PubMed ID: 15274684
[TBL] [Abstract][Full Text] [Related]
17. Prognostic implications of left ventricular mass and geometry following myocardial infarction: the VALIANT (VALsartan In Acute myocardial iNfarcTion) Echocardiographic Study.
Verma A; Meris A; Skali H; Ghali JK; Arnold JM; Bourgoun M; Velazquez EJ; McMurray JJ; Kober L; Pfeffer MA; Califf RM; Solomon SD
JACC Cardiovasc Imaging; 2008 Sep; 1(5):582-91. PubMed ID: 19356485
[TBL] [Abstract][Full Text] [Related]
18. Angiotensin receptor antagonist regresses left ventricular hypertrophy associated with diabetic nephropathy in dialysis patients.
Kanno Y; Kaneko K; Kaneko M; Kotaki S; Mimura T; Takane H; Suzuki H
J Cardiovasc Pharmacol; 2004 Mar; 43(3):380-6. PubMed ID: 15076221
[TBL] [Abstract][Full Text] [Related]
19. Long-term treatment with valsartan improved cyclic variation of the myocardial integral backscatter signal and diastolic dysfunction in hypertensive patients: the echocardiographic assessment.
Mizuta Y; Kai H; Mizoguchi M; Osada K; Tahara N; Nakaura H; Kuwahara F; Imaizumi T;
Hypertens Res; 2008 Oct; 31(10):1835-42. PubMed ID: 19015589
[TBL] [Abstract][Full Text] [Related]
20. Comparison of the effects of three angiotensin II receptor type 1 blockers on metabolic parameters in hypertensive patients with type 2 diabetes mellitus.
Ozaki N; Nomura Y; Sobajima H; Kondo K; Oiso Y
Eur J Intern Med; 2010 Jun; 21(3):236-9. PubMed ID: 20493430
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
